FOOD AND DRUG ADMINISTRATION
ANTIVIRAL DRUGS ADVISORY COMMITTEE (AVAC) MEETING
October 4, 2001
NDA 21-266, Vfend™ (voriconazole) Tablets, and NDA 21-267, Vfend™ I.V. (voriconazole) for infusion, Pfizer Global Research and Development
Proposed for the treatment of invasive aspergillosis, serious Candida infections, infections caused by Scedosporium spp. and Fusarium spp., rare and refractory infections and empirical treatment of febrile neutropenia.
Sponsor Presentation Pfizer Global Research & Development
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Main Presentation, Reinhard Baildon, MD ppt html
Thomas Patterson, MD ppt html
Main Efficacy, Helen Whamond Boucher, MD ppt html
FDA Presentation, Rosemary Tiernan MD ppt html
Empiric Antifungal Therapy of Febrile Neutropenic Patients, John H Powers MD ppt html
Questions ppt html